ANGN 10 (+2.04%)
US03476J1079BiotechnologyBiotechnology

Angion Biomedica (ANGN) Stock Highlights

10 | +2.04%
2023-07-06 19:55:33
Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Statistics

Range Today
8.9 10.6
Volume Today 22.36K
Range 1 Year
4.6 20.4
Volume 1 Year 2.4M
Range 3 Year
4.6 263
Volume 3 Year 7.67M
Range 10 Year
4.6 263
Volume 10 Year 7.67M

Highlights

Market Capitalization 30.11M (micro)
Floating Shares 20.9M
Current Price 10
Price To Earnings -0.1
Price To Revenue 1.82
Price To Book 0.76
Earnings Per Share -10.11
Payout Ratio 0%

Performance

Latest +2.04%
1 Month +46.63%
3 Months +47.28%
6 Months +16.28%
1 Year -37.89%
3 Years -94.32%
5 Years -94.32%
10 Years -94.32%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.